Table 1.
Effectiveness of UV devices on reducing MDROs on carriers
| Author, year | UV system | MDROs | Time (min) | Energy (µW/cm2) | Log10 reduction direct (indirect) |
|---|---|---|---|---|---|
| Rutala, 201027 | UV-C, Tru-D | MRSA, VRE, A | ~15 | 12,000 | 4.31 (3.85), 3.90 (3.25), 4.21 (3.79) |
| Rutala, 201027 | UV-C, Tru-D | Cd | ~50 | 36,000 | 4.04 (2.43) |
| Boyce, 201128 | UV-C, Tru-D | Cd | 67.8 (1 stage) | 22,000 | 1.7-2.9 |
| Havill, 201229 | UV-C, Tru-D | Cd | 73 (mean) | 22,000 | 2.2 |
| Rutala, 201330 | UV-C, Tru-D | MRSA | 25 | 12,000 | 4.71 (4.27) |
| Rutala, 201330 | UV-C, Tru-D | Cd | 43 | 22,000 | 3.41 (2.01) |
| Mahida, 201331 | UV-C, Tru-D | OR: MRSA, VRE | 49 | 12,000 | ≥4.0 (≥4.0), 3.5 (2.4) |
| Mahida, 201331 | UV-C, Tru-D | Single patient room: VRE, A, As | 23-93 | 12,000 | ≥4.0 (>2.3), ≥4.0 (1.7), ≥4.0 (2.0) |
| Rutala, 201432 | UV-C, Optimum | MRSA | 5 | NS | 4.10 (2.74) |
| Rutala, 201432 | UV-C, Optimum | Cd | 10 | NS | 3.35 (1.80) |
| Nerandzic, 201533 | UV, PX, Xenon | Cd, MRSA, VRE | 10 at 4 ft (2 cycles) | NS | 0.55, 1.85, 0.6 |
A, Acinetobacter spp; As, Aspergillus; Cd, Clostridium difficile; MDRO, multidrug-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus; NS, not stated; OR, operating room; PX, pulsed xenon; UV, ultraviolet light; VRE, vancomycin-resistant enterococci.